products
Home » Archives for products
FDA To Baxter: Start Telling The Truth
Tuesday, August 31st, 2010
File this under three strikes and you’re out: Baxter Healthcare was dinged by the FDA for circulating a brochure for its Aralast NP emphysema treatment that contains misleading efficacy claims.
Posted in: Regulatory | 0 Comments »
Read the full story
J&J Plagued by Product Recalls
Monday, August 30th, 2010
Zacks.com submits: Johnson & Johnson ( JNJ ) took another hit recently with the company announcing yet another product recall. This time round, the company said that it is voluntarily recalling two hip replacement systems – the ASR XL Acetabular System and DePuy ASR Hip Resurfacing System. The company decided to issue the product recall as it was observed that several patients using the products required a second hip replacement procedure or a revision surgery
Posted in: Pharma News | 0 Comments »
Read the full story
Promising Results Reported for Cholesterol and Hepatitis C Drugs
Thursday, August 5th, 2010
New drugs for hepatitis C and superhigh cholesterol succeeded in late-stage clinical trials, the developers of the products announced on Wednesday.
Posted in: headlines | 0 Comments »
Read the full story
For One Drugmaker, Outsourcing Is A Problem
Wednesday, July 28th, 2010
In this day and age where drugmakers are trying harder all the time to outsource work in hopes of cutting expenses, it is worth remembering this approach can have a downside. River’s Edge Pharmaceuticals is learning this lesson
Posted in: Regulatory | 0 Comments »
Read the full story
How Brand-Name Drugmakers Fight Generics
Thursday, July 22nd, 2010
With all those patent expirations under way, brand-name drugmakers, of course, are desperate to wring as much money as possible out of their products. So how do they counter the generic onslaught
Posted in: Regulatory | 0 Comments »
Read the full story
The Value of an SPA for Avanir Pharmaceuticals
Thursday, July 22nd, 2010
Sheff Station submits: There are only two companies that will be up for FDA approval for their products in the second half of the year that have an SPA (special protocol assessment) with the FDA. Those companies are Avanir Pharmaceuticals ( AVNR ) and Vivus Pharmaceuticals ( VVUS )
Posted in: Pharma News | 0 Comments »
Read the full story
Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes
Monday, July 19th, 2010
The Burrill Report submits: GlaxoSmithKline ( GSK ) said that it expects to record a legal charge for the second quarter of 2010 of $2.36 billion relating to settlements of product liability litigation concerning its diabetes drug Avandia and anti-trust litigations relating to Paxil and other products, as well as the U.S. government’s investigation into its former manufacturing facility in Cidra, Puerto Rico. The company confirms it has reached an agreement in principle with the U.S
Posted in: Pharma News | 0 Comments »
Read the full story
Corn Products to Buy Akzo’s National Starch Division (Update5)
Monday, June 21st, 2010
June 21 (Bloomberg) — Corn Products International Inc., a U.S. corn refiner and maker of sweeteners, agreed to acquire Akzo Nobel NV’s National Starch unit for $1.3 billion in cash to add products and customers globally.The purchase of National Starch, which makes biscuit and cake ingredients,… Food Product Design – Corn Products to Acquire National Starch for $1.3 Billion Just Food – UPDATE: US: Corn Products sees European benefit from National Starch deal
Posted in: headlines | 0 Comments »
Read the full story
Indian biotechs shift focus to new collaboration deals
Monday, June 7th, 2010
India’s biotech industry is reporting a surge of new drug development collaborations as Big Pharma companies remodel their R&D strategies and look to cut costs and share risk.
Posted in: Pharma News | 0 Comments »
Read the full story
Now, it could be that management was guided by their stock price
Tuesday, June 1st, 2010
In the age of information it’s amazing that ANY company would try and hide anything from the public or investigators. But, let’s be honest, this is what happens when investors interests are put ahead of patients & customers interests
Posted in: DTC | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice